Diskussion:MDMA

message: Systematische Reviews:
Benjamin JG Illingworth A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis, 
Results:
Four randomised controlled trials (RCTs) met inclusion criteria. When compared to active placebo, intervention groups taking 75 mg (MD −46.90; 95% (confidence intervals) CI −58.78, −35.02), 125 mg (MD −20.98; 95% CI −34.35, −7.61) but not 100 mg (MD −12.90; 95% CI −36.09, 10.29) of MDMA with psychotherapy, had significant decreases in CAPS-IV scores, as did the inactive placebo arm (MD −33.20; 95% CI −40.53, −25.87). A significant decrease in BDI when compared to active placebo (MD −10.80; 95% CI −20.39, −1.21) was only observed at 75 mg. Compared to placebo, participants reported significantly more episodes of low mood, nausea and jaw-clenching during sessions and lack of appetite after 7 days.
Conclusion:
These results demonstrate potential therapeutic benefit with minimal physical and neurocognitive risk for the use of MDMA-assisted psychotherapy in TR-PTSD, despite little effect on Beck’s Depression Inventory. Better powered RCTs are required to investigate further.
MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was −24.4 (s.d. 11.6) in the MDMA group and −13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities.
Sessa et al.: First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder   
Results: MDMA treatment was well tolerated by all participants. No unexpected adverse events were observed. Psychosocial functioning improved across the cohort. Regarding alcohol use, at nine months post detox, the average units of alcohol consumption by participants was 18.7 units per week compared to 130.6 units per week before the detox. This compares favourably to a previous observational study (the 'Outcomes' study) by the same team with a similar population of people with AUD.
Conclusions: This study provides preliminary support for the safety and tolerability of a novel intervention for AUD post detox. Further trials to examine better the therapeutic potential of this approach are now indicated.
Mithoefer et al.: The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
Aus dem Abstract: Decrease in Clinician-Administered PTSD Scale scores from baseline was significantly greater for the group that received MDMA than for the placebo group at all three time points after baseline. The rate of clinical response was 10/12 (83%) in the active treatment group versus 2/8 (25%) in the placebo group. There were no drug-related serious adverse events, adverse neurocognitive effects or clinically significant blood pressure increases. MDMA-assisted psychotherapy can be administered to posttraumatic stress disorder patients without evidence of harm, and it may be useful in patients refractory to other treatments.
Thal/Lommen: Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder: 
Thus far, an overall remission rate of 66.2% and low rates of adverse effects have been found in the six phase two trials conducted in clinical settings with 105 blinded subjects with chronic PTSD. The results seem to support MDMA’s safe and effective use as an adjunct to psychotherapy. Even though preliminary studies may look promising, more studies of its application in a psychotherapeutic context are needed in order to establish MDMA as a potential adjunct to therapy.
Wang et al: Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder
Results: Adherence rating scores were high across cotherapist dyads (M = 95.08%, SD = 3.70%) and sites (M = 95.23%, SD = 2.20%). CAPS-5 scores decreased following 3 MDMA-AT sessions at 18 weeks post baseline (ΔM = −29.99, ΔSD = 13.45, p < .0001, n = 37, Cohen’s d = 2.2, confidence interval [1.97, 2.47]). MDMA was well tolerated. Conclusions: These findings corroborate previous results that MDMA-AT can achieve significant improvements in PTSD symptom severity and demonstrate scalability of manualized therapy across clinic sites in the United States and Canada.
etc pp. Die Botschaft wiederholt sich: Hohe Effektivität bei geringen Nebenwirkungen. Das steht völllig im Gegensatz zum bisherigen Tenor des Abschnitts. --Johannes Rohr (Diskussion) 07:39, 25. Dez. 2021 (CET)
thread_title:  Veröffentlichte Studien zu MDMA-unterstützter Psychotherapie 

message: Was es alles gibt: Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems Gruß, --Sti (Diskussion) 11:57, 3. Jan. 2022 (CET)
thread_title:  Post COVID-19 

message: Ich habe eben versucht den Satz zur Schlafapnoe-Studie anzupassen. Ich bin leider zu früh auf Enter gekommen und meine unfertige Formulierung wurde noch beim Bearbeiten abgesendet und folglich abgelehnt.
Meiner Meinung nach ist der aktuelle Satz zur Studie aber im Artikel faktisch falsch: Es wird behauptet, dass ein erhöhtes Risiko einer Schlafapnoe durch MDMA-Konsum nachgewiesen wurde. Es wurde jedoch lediglich festgestellt, dass MDMA-Konsumenten nach Konsum häufiger eine Schlafapnoe aufweisen.
Es kann ja auch beispielsweise sein, dass umgekehrt Schlafapnoe-Patienten durch ihr Leiden statistisch ein höheres Risiko haben zu MDMA "zu greifen".
Oder sehe ich hier etwas falsch? Falls nicht, mag das jemand umformulieren? --Alpenwiese (Diskussion) 14:55, 1. Feb. 2024 (CET)
replies: text: Einwand war berechtigt. Habe die Sache bereinigt und notwendige Sekundärliteratur hinzugefügt. --Saidmann (Diskussion) 16:25, 1. Feb. 2024 (CET)
thread_title:  Schlafapnoe-Studie